Paper Details

  1. Home
  2. Paper Details

Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.

Author: JiYing, JiangQian, JuLi-Li, TangXun, WuKai-Hua, YangYong-Feng, YuMin-Min

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Telbivudine and lamivudine were both effective in reducing HBV DNA levels in pregnant women and interrupting perinatal transmission of hepatitis B virus. Both drugs were safe for mothers and children.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Infection with hepatitis B virus (HBV) during pregnancy may lead to perinatal transmission. OBJECTIVES: To compare the efficacy and safety of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. STUDY DESIGN: All pregnant women enrolled in this stu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jcv.2014.06.005

データ提供：米国国立医学図書館（NLM）

Comparing Telbivudine and Lamivudine for Hepatitis B Prevention

Hepatitis B virus (HBV) infection can be transmitted from mother to child during pregnancy, potentially leading to serious health consequences for the child. This study aims to compare the effectiveness and safety of two antiviral medications, telbivudine and lamivudine, in preventing perinatal transmission of HBV.

The researchers enrolled pregnant women with HBV infection and assigned them to receive either telbivudine, lamivudine, or hepatitis B immune globulin (HBIG) injection. They then compared the rates of HBV transmission and the safety of these treatments.

Their findings indicated that both telbivudine and lamivudine were effective in reducing HBV viral load and preventing perinatal transmission. Both medications showed similar levels of effectiveness and safety, making them valuable tools for preventing HBV transmission from mothers to their children.

Protecting Against Perinatal HBV Transmission

This study provides crucial information for preventing perinatal HBV transmission. It shows that both telbivudine and lamivudine are effective and safe options for pregnant women with HBV infection, offering a valuable means of safeguarding children from this potentially serious disease.

Ensuring Healthy Outcomes for Mothers and Babies

The findings of this study are encouraging for both mothers and babies. It provides a framework for managing HBV infection during pregnancy and minimizing the risk of transmission to the child.

Dr.Camel's Conclusion

This research is a testament to the incredible strides made in preventing and managing infectious diseases. By harnessing the power of antiviral medications, we can protect mothers and their children from the devastating consequences of HBV infection.

Date :
  1. Date Completed 2015-03-30
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

24994007

DOI: Digital Object Identifier

10.1016/j.jcv.2014.06.005

Related Literature

Article Analysis
・Side Effects of telbivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.